SecBot SecBot
COURT-RULING ·Filed Jul 30, 2026

RHHBY

In re Subpoena to Genentech
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago CourtCourt Ruling · govinfo.gov
Court ruling (district)
Actionable Insight • Neutral

This is a routine procedural ruling with no financial or operational impact on Genentech/Roche. No trading action warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
RHHBY ▲ +9.86% at T+60d
NEUTRAL call +9.86% · α vs SPY +7.15% · entry $54.67 → $60.06
Entry = T+0 close
Jul 31, 2026
via day close
T+1d
+0.75%
call +0.75% · α -0.67%
$55.08
settled 3mo ago
T+5d
+4.74%
call +4.74% · α +1.23%
$57.26
settled 3mo ago
T+20d
+0.95%
call +0.95% · α -2.04%
$55.19
settled 2mo ago
T+60d
+9.86%
call +9.86% · α +7.15%
$60.06
settled yesterday

Price Chart

Loading chart...

Executive Summary

A federal magistrate judge granted Regeneron's motion to transfer a subpoena dispute involving Genentech from the Northern District of California to the District of Massachusetts, where the underlying qui tam litigation has been pending for nearly six years. The ruling is a routine procedural venue transfer with no financial exposure or business impact on Genentech, which conceded Massachusetts was the proper forum.

Court Ruling Details

Ruling Date
Jul 30, 2026
Court
United States District Court for the Northern District of California
Court Level
District
Judge
Alex G. Tse
Case Type
other
Ruling Type
procedural
Outcome
PARTIAL — mixed ruling, some claims won/lost
Precedent Risk
LOW

Key Facts

  • Genentech is a non-party subpoena recipient in a qui tam case against Regeneron in Massachusetts.
  • The court found exceptional circumstances under Rule 45(f) and transferred the motion to compel to the District of Massachusetts.
  • Genentech conceded Massachusetts was the proper forum and did not dispute that similar subpoenas were being litigated there.
  • No damages, injunction, or financial exposure to Genentech is at issue in this procedural ruling.

Financial Impact

None — purely procedural venue ruling with no financial exposure to Genentech.

Risk Factors

  • No material risk identified — the ruling concerns only the proper venue for a discovery dispute in which Genentech is a non-party.

Market Snapshot

Analyst Consensus
50% bullish (28 analysts)

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-cc36c2a367-RHHBY
4 reports for RHHBY
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for RHHBY — sortable, filterable
TypeNow
Oct 23, 2026
4d ago
Court Ruling
NEUTRAL ★ 4/10
$59.82awaiting T+5—$60.14 (+0.53%)
Oct 13, 2026
14d ago
Court Ruling
BULLISH ★ 6/10
$55.69 $59.11▲ +6.14%▲ +5.69%$60.14 (+7.99%)
Aug 14, 2026
10w ago
Court Ruling
BULLISH ★ 6/10
$54.61 $57.47▲ +5.24%▲ +6.43%$60.14 (+10.13%)
Jul 30, 2026
12w ago
Court Ruling
NEUTRAL ★ 2/10
$54.67 $57.26▲ +4.74%▲ +1.23%$60.14 (+10.01%)
Showing 4 of 4

US Market Status

Market Open — Closes in 4h 28m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · govinfo.gov Report published Jul 31, 2026